Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Xerecept

2004 FOUNDED
M&A STATUS
Undetermined LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

A steroid used to reduce brain swelling associated with tumors. Xerecept owned by Neurobiological Tech is used on pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with cerebral tumors

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 2000 Powell Street
  • Suite 800
  • Emeryville, CA 94608
  • United States

Xerecept Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Xerecept‘s full profile, request access.

Request full access to PitchBook

Xerecept Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Xerecept‘s full profile, request access.

Request full access to PitchBook

Xerecept Executive Team (5)

Name Title Board
Seat
Contact
Info
Abraham Cohen Chairman
Paul Freiman President & Chief Executive Officer
David Levy Vice President

2 Former Executives

You’re viewing 3 of 5 executives. Get the full list »

Xerecept Board Members (1)

Name Representing Role Since Contact
Info
0000000 00000 Xerecept Chairman 000 0000